Devsi Jamil Alnoor, Paquette Vanessa, Carr Roxane R
, PharmD, ACPR, is with the Department of Pharmacy, Children's & Women's Health Centre of British Columbia, Lower Mainland Pharmacy Services, and the Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia.
, BSc(Pharm), ACPR, PharmD, is with the Department of Pharmacy, Children's & Women's Health Centre of British Columbia, Lower Mainland Pharmacy Services, and the Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia.
Can J Hosp Pharm. 2024 Jun 12;77(2):e3525. doi: 10.4212/cjhp.3525. eCollection 2024.
Extravasation is the erroneous delivery of IV medication or fluid into the extravascular space. Complications ranging from mild injury to amputation can result, depending on the physical and pharmacologic properties of the infusate. Children are at increased risk for extravasation injuries. There is a paucity of data on the treatment and outcomes of extravasation injuries, particularly in terms of the role of pharmacologic antidotes.
To describe the incidence of extravasation at a tertiary pediatric care centre (as an update to a previous study), to identify the agents most commonly involved in extravasation injuries, to describe the antidotes used for management of injuries and their related adverse drug effects, and to describe complications related to injuries.
The medical records of pediatric patients who experienced an extravasation injury at the BC Children's and BC Women's Hospitals, between September 1, 2008, and September 30, 2020, were reviewed. Data regarding management (adherence with institutional protocol) and outcomes of injuries were collected.
The 242 charts included in the analysis noted a total of 245 extravasation injuries, for an extravasation incidence of 0.04% per patient-day. Of the 242 patients, 110 were excluded from secondary outcome analysis due to lack of data detailing the extravasation event. Of the remaining 132 patients, the majority were neonates ( = 54, 40.9%), infants ( = 33, 25.0%), and children ( = 34, 25.8%), and more than a third were treated on general pediatric wards ( = 50, 37.9%). The medications most frequently involved were total parenteral nutrition with lipids (36/132, 27.3%), vancomycin (36/132, 27.3%), and IV fluids (35/132, 26.5%). Most of the patients had mild outcomes and recovered without complications. No adverse drug events from antidotes were reported.
The incidence of extravasation at the study institution remained low, with the medications involved being similar to those reported in the literature and the majority of patients having mild outcomes. Additional prospective studies are needed to assess the efficacy and safety of antidotes administered for extravasation injuries.
药物外渗是指静脉注射药物或液体错误地进入血管外间隙。根据输注液的物理和药理特性,可能会导致从轻度损伤到截肢等一系列并发症。儿童发生药物外渗损伤的风险更高。关于药物外渗损伤的治疗和结局的数据较少,尤其是在药理解毒剂的作用方面。
描述一家三级儿科护理中心的药物外渗发生率(作为对先前研究的更新),确定最常导致药物外渗损伤的药物,描述用于处理损伤的解毒剂及其相关的药物不良反应,并描述与损伤相关的并发症。
回顾了2008年9月1日至2020年9月30日期间在不列颠哥伦比亚省儿童医院和不列颠哥伦比亚省妇女医院发生药物外渗损伤的儿科患者的病历。收集了有关处理(是否遵循机构方案)和损伤结局的数据。
分析中纳入的242份病历共记录了245例药物外渗损伤,药物外渗发生率为每患者日0.04%。在这242例患者中,110例因缺乏详细描述药物外渗事件的数据而被排除在次要结局分析之外。在其余132例患者中,大多数是新生儿(54例,40.9%)、婴儿(33例,25.0%)和儿童(34例,25.8%),超过三分之一的患者在普通儿科病房接受治疗(50例,37.9%)。最常涉及的药物是含脂质的全胃肠外营养(36/132,27.3%)、万古霉素(36/132,27.3%)和静脉输液(35/132,26.5%)。大多数患者结局较轻,无并发症康复。未报告解毒剂引起的药物不良事件。
研究机构的药物外渗发生率仍然较低,所涉及的药物与文献报道相似,大多数患者结局较轻。需要进行更多的前瞻性研究来评估用于药物外渗损伤的解毒剂的疗效和安全性。